Donor and recipient characteristics
| . | PBHSCT group (N = 24) . | BMT group (N = 27) . | P . |
|---|---|---|---|
| Age, median (range) | |||
| Donors | 33 (22-51) | 33 (20-63) | .70 |
| Recipients | 35 (21-51) | 34 (20-50) | .88 |
| Sex mismatch, donor → recipient | |||
| Female → female (%), [parous donors] | 5 (21) [2] | 3 (11) [2] | — |
| Female → male (%), [parous donors] | 6 (25) [6] | 5 (19) [2] | — |
| Male → female (%) | 4 (17) | 10 (37) | — |
| Male → male (%) | 9 (38) | 9 (33) | .42 |
| Donors (%) | |||
| Nulliparous females | 3 (13) | 4 (15) | — |
| Parous females | 8 (33) | 4 (15) | — |
| Males | 13 (54) | 19 (70) | .33 |
| Diagnosis (%) | |||
| AML | 10 (42) | 11 (41) | — |
| ALL | 3 (12) | 6 (22) | — |
| CML | 11 (46) | 10 (37) | .70 |
| Conditioning regimen (%) | |||
| TBI-EDX | 17 (71) | 15 (56) | — |
| BUS-EDX | 6 (25) | 6 (22) | — |
| VP16-EDX-TBI + TAME | 1 (4) | 6 (22) | .18 |
| . | PBHSCT group (N = 24) . | BMT group (N = 27) . | P . |
|---|---|---|---|
| Age, median (range) | |||
| Donors | 33 (22-51) | 33 (20-63) | .70 |
| Recipients | 35 (21-51) | 34 (20-50) | .88 |
| Sex mismatch, donor → recipient | |||
| Female → female (%), [parous donors] | 5 (21) [2] | 3 (11) [2] | — |
| Female → male (%), [parous donors] | 6 (25) [6] | 5 (19) [2] | — |
| Male → female (%) | 4 (17) | 10 (37) | — |
| Male → male (%) | 9 (38) | 9 (33) | .42 |
| Donors (%) | |||
| Nulliparous females | 3 (13) | 4 (15) | — |
| Parous females | 8 (33) | 4 (15) | — |
| Males | 13 (54) | 19 (70) | .33 |
| Diagnosis (%) | |||
| AML | 10 (42) | 11 (41) | — |
| ALL | 3 (12) | 6 (22) | — |
| CML | 11 (46) | 10 (37) | .70 |
| Conditioning regimen (%) | |||
| TBI-EDX | 17 (71) | 15 (56) | — |
| BUS-EDX | 6 (25) | 6 (22) | — |
| VP16-EDX-TBI + TAME | 1 (4) | 6 (22) | .18 |
AML indicates acute myeloid leukemia; ALL, acute lymphoid leukemia; CML, chronic myeloid leukemia; TBI, total body irradiation (median, 12 Gy; range, 11-13.5); EDX, cyclophosphamide (120 mg/kg); BUS, busulfan (16 mg/kg orally); VP16, vepeside (20 mg/kg); and TAME, TBI plus aracytine (12 g/m2) plus melphalan (140 mg/m2) plus etoposide (60 mg/kg).